PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Eli Lilly receives marketing authorisation for baricitinib

Treatment involves adult patients with severe alopecia areata.

Eli Lilly has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for baricitinib – also known as Olumiant – for the treatment of severe alopecia areata in adult patients.

Marketing authorisation was based on BRAVE-AA1 and BRAVE-AA2 studies which both used the Severity of Alopecia Tool (SALT) score and both met the primary endpoint among the proportion of patients.

Meanwhile, achievement of full regrowth or regrowth with minimal gaps in eyebrow and eyelash hair was also seen, with baricitinib, for patients who at baseline had significant gaps or no notable eyebrows or eyelashes, as compared to patients taking placebo

Sue Schilling, chief executive of Alopecia UK, welcomed the news: “This authorisation may lead to further treatment options now being offered to those eligible patients struggling with alopecia areata.

“We will continue to ensure our voice is heard where appropriate and will try to demonstrate the psychological, social and financial impacts that alopecia areata can have on a person’s life to emphasise the importance of having access to treatments.”

“This authorisation establishes baricitinib as the first JAK inhibitor to be authorised in Britain for the treatment of adults with severe alopecia areata and reflects our commitment to immunological diseases with high unmet need,” concluded Dr Jeff Yang, associate vice president at Eli Lilly.

“We understand the importance of establishing a novel treatment option for eligible patients and Lilly would like to thank the patients and investigators around the world who have made this possible,” he added.

Baricitinib has now become the first licensed JAK inhibitor for the treatment of severe alopecia areata.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026